Following the news, La Jolla Pharmaceutical's stock price spiked 81%, trading at $36.15 per share, up $16.28, on Monday afternoon. (See also, Boston Scientific Recalls Lotus Heart Devices.) In the placebo-compared Phase 3 study of LJPC
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,123,456 and 18,261,557 shares issued and …
KHQ1mon
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,123,456 and 18,261,557 shares issued and …
WFMJ1mon
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company), a leader in the development of …
Taking Stock with Kathleen Hays and Pimm Fox. Guest: Bloomberg stocks editor David Wilson on today’s market winners, losers, and Stock of the Day: La Jolla Pharmaceutical (LJPC). producer: Samara Lenga +1-212-617-2984 or …
The stock price is soaring for local drugmaker La Jolla Pharmaceutical Co. following promising clinical trial data on its experimental blood pressure drug. The local company is studying the drug, called LJPC-501, in patients who have …
LJPC) on Tuesday, September 8 with “Buy” rating. The stock has “Hold” rating by Zacks on Tuesday, August 11. The …
Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …
While investors were not satisfied with the results, Chardan's Gbola Amusa maintains a Buy rating on La Jolla's stock with an unchanged $34 price target. The analyst, who also holds an MD, argued in a research report that LJPC-501 showed …
After announcing that its phase 3 ATHOS-3 study would be published in a prestigious medical journal, clinical-stage biotech La Jolla Pharmaceutical (NASDAQ: LJPC) saw its shares ... David and Tom Gardner have a stock tip, it can …